| Product Code: ETC9974865 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Summon Dutta | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United States (US) RNA Market Overview |
3.1 United States (US) Country Macro Economic Indicators |
3.2 United States (US) RNA Market Revenues & Volume, 2021 & 2031F |
3.3 United States (US) RNA Market - Industry Life Cycle |
3.4 United States (US) RNA Market - Porter's Five Forces |
3.5 United States (US) RNA Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.6 United States (US) RNA Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 United States (US) RNA Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing research and development activities in the field of genomics and personalized medicine. |
4.2.2 Rising prevalence of chronic diseases driving demand for RNA-based therapeutics. |
4.2.3 Technological advancements in RNA sequencing and gene editing techniques. |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for RNA-based therapies. |
4.3.2 High cost associated with RNA sequencing and manufacturing processes. |
4.3.3 Limited awareness and adoption of RNA-based products among healthcare providers and patients. |
5 United States (US) RNA Market Trends |
6 United States (US) RNA Market, By Types |
6.1 United States (US) RNA Market, By Application |
6.1.1 Overview and Analysis |
6.1.2 United States (US) RNA Market Revenues & Volume, By Application, 2021- 2031F |
6.1.3 United States (US) RNA Market Revenues & Volume, By Clinical Diagnostic, 2021- 2031F |
6.1.4 United States (US) RNA Market Revenues & Volume, By Drug Discovery, 2021- 2031F |
6.1.5 United States (US) RNA Market Revenues & Volume, By Toxicogenomic, 2021- 2031F |
6.1.6 United States (US) RNA Market Revenues & Volume, By Other, 2021- 2031F |
6.2 United States (US) RNA Market, By End User |
6.2.1 Overview and Analysis |
6.2.2 United States (US) RNA Market Revenues & Volume, By Pharmaceutical & Biotechnology Companies, 2021- 2031F |
6.2.3 United States (US) RNA Market Revenues & Volume, By Hospitals And Diagnostic Centers, 2021- 2031F |
6.2.4 United States (US) RNA Market Revenues & Volume, By Others, 2021- 2031F |
7 United States (US) RNA Market Import-Export Trade Statistics |
7.1 United States (US) RNA Market Export to Major Countries |
7.2 United States (US) RNA Market Imports from Major Countries |
8 United States (US) RNA Market Key Performance Indicators |
8.1 Number of clinical trials using RNA-based therapies. |
8.2 Adoption rate of RNA sequencing technologies in clinical diagnostics. |
8.3 Investment in RNA-focused biotech companies. |
8.4 Number of research publications on RNA therapeutics and technologies. |
8.5 Growth in the number of patents related to RNA-based products and technologies. |
9 United States (US) RNA Market - Opportunity Assessment |
9.1 United States (US) RNA Market Opportunity Assessment, By Application, 2021 & 2031F |
9.2 United States (US) RNA Market Opportunity Assessment, By End User, 2021 & 2031F |
10 United States (US) RNA Market - Competitive Landscape |
10.1 United States (US) RNA Market Revenue Share, By Companies, 2024 |
10.2 United States (US) RNA Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here